<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00101062</url>
  </required_header>
  <id_info>
    <org_study_id>040402-4671; CDR0000407502</org_study_id>
    <secondary_id>P30CA072720</secondary_id>
    <secondary_id>CINJ-NJ1103</secondary_id>
    <secondary_id>CINJ-5076v3</secondary_id>
    <secondary_id>CINJ-040402</secondary_id>
    <secondary_id>UMDNJ-4761</secondary_id>
    <nct_id>NCT00101062</nct_id>
  </id_info>
  <brief_title>Letrozole and Celecoxib in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer</brief_title>
  <official_title>Phase II Study of Letrozole (Femara) and Celecoxib (Celebrex) in Postmenopausal Women With Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Medicine and Dentistry of New Jersey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Rutgers, The State University of New Jersey</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using&#xD;
      letrozole may fight breast cancer by lowering the amount of estrogen the body makes.&#xD;
      Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell&#xD;
      growth and by blocking blood flow to the tumor. Giving letrozole with celecoxib may kill more&#xD;
      tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well letrozole and celecoxib work in treating&#xD;
      postmenopausal women with locally advanced or metastatic breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the response rate in postmenopausal women with hormone receptor-positive&#xD;
           locally advanced or metastatic adenocarcinoma of the breast treated with letrozole and&#xD;
           celecoxib as first-line therapy.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the time to disease progression and overall survival of patients treated with&#xD;
           this regimen.&#xD;
&#xD;
        -  Determine the toxicity of this regimen in these patients.&#xD;
&#xD;
        -  Compare cyclooxygenase activity in blood and tumor cells from these patients before and&#xD;
           after treatment with this regimen.&#xD;
&#xD;
        -  Determine the effect of this regimen on aromatase activity, tumor proliferation, and&#xD;
           angiogenesis in tumor samples from these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive oral letrozole once daily and oral celecoxib twice daily on days 1-28.&#xD;
      Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed for survival.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 45-72 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    study drug unavailable&#xD;
  </why_stopped>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">December 2005</completion_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>celecoxib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>letrozole</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed adenocarcinoma of the breast&#xD;
&#xD;
               -  Locally advanced or metastatic disease&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
               -  No bone disease only&#xD;
&#xD;
          -  No history of brain metastases unless controlled with radiotherapy or surgical&#xD;
             resection for ≥ 6 months before study entry&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Estrogen receptor- OR progesterone receptor-positive&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status&#xD;
&#xD;
          -  Postmenopausal, as defined by 1 of the following:&#xD;
&#xD;
               -  Prior bilateral oophorectomy&#xD;
&#xD;
               -  Prior bilateral ovarian irradiation&#xD;
&#xD;
               -  No spontaneous menstrual bleeding within the past 12 months&#xD;
&#xD;
               -  Age 55 and over AND prior hysterectomy without oophorectomy&#xD;
&#xD;
               -  Age 54 and under AND prior hysterectomy without oophorectomy (or status of&#xD;
                  ovaries is unknown) AND documented follicle-stimulating hormone level in&#xD;
                  postmenopausal range&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Granulocyte count ≥ 1,000/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No prior allergic reaction attributed to compounds of similar chemical or biologic&#xD;
             composition to study drugs&#xD;
&#xD;
          -  No prior allergic reaction to sulfonamides&#xD;
&#xD;
          -  No active peptic ulcer disease&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No other medical condition that would preclude study participation&#xD;
&#xD;
          -  Able to swallow oral medication&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy for metastatic or recurrent disease&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No prior endocrine therapy for metastatic disease&#xD;
&#xD;
               -  Prior adjuvant tamoxifen allowed&#xD;
&#xD;
          -  No prior aromatase inhibitors&#xD;
&#xD;
          -  No prior hormonal therapy for recurrent disease&#xD;
&#xD;
          -  No other concurrent hormonal therapy&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  See Menopausal status&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  See Menopausal status&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No concurrent fluconazole or lithium&#xD;
&#xD;
          -  No concurrent aspirin, non-steroidal anti-inflammatory drugs, or other&#xD;
             cyclooxygenase-2 inhibitors&#xD;
&#xD;
               -  Concurrent chronic cardioprotective low-dose aspirin allowed&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antoinette R. Tan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Rutgers Cancer Institute of New Jersey</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicaltrials.gov/ct2/show/NCT00101062</url>
    <description>Clinical trial summary from the National Cancer Institute's PDQ® database</description>
  </link>
  <verification_date>June 2011</verification_date>
  <study_first_submitted>January 7, 2005</study_first_submitted>
  <study_first_submitted_qc>January 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2005</study_first_posted>
  <last_update_submitted>June 3, 2011</last_update_submitted>
  <last_update_submitted_qc>June 3, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2011</last_update_posted>
  <responsible_party>
    <name_title>Antionette Tan, MD</name_title>
    <organization>UMDNJ/CINJ</organization>
  </responsible_party>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

